Article
Urology & Nephrology
Matthew R. Weir, April Slee, Tao Sun, Dainius Balis, Richard Oh, Dick de Zeeuw, Vlado Perkovic
Summary: The study showed that there were no significant effects of canagliflozin on serum potassium levels in the overall population or key subgroups in the CANVAS Program. Adverse events of hyperkalemia were uncommon and occurred at comparable rates with canagliflozin and placebo.
CLINICAL KIDNEY JOURNAL
(2021)
Article
Cardiac & Cardiovascular Systems
Muthiah Vaduganathan, Naveed Sattar, Jialin Xu, Javed Butler, Kenneth W. Mahaffey, Bruce Neal, Wayne Shaw, Norman Rosenthal, Michael Pfeifer, Michael K. Hansen, James L. Januzzi
Summary: This study found that canagliflozin, an SGLT2 inhibitor, delays the increase of hs-cTnT and sST2 and reduces the occurrence of heart failure and kidney events. High levels of hs-cTnT and sST2, along with other cardiovascular biomarkers, can predict cardiovascular and kidney outcomes and may influence the treatment effects of canagliflozin.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2022)
Article
Cardiac & Cardiovascular Systems
Ashish Sarraju, George Bakris, Christopher P. Cannon, David Cherney, C. V. Damaraju, Gemma A. Figtree, Jagadish Gogate, Tom Greene, Hiddo J. L. Heerspink, James L. Januzzi, Bruce Neal, Meg J. Jardine, Jaime Blais, Mikhail Kosiborod, Adeera Levin, Ildiko Lingvay, Matthew R. Weir, Vlado Perkovic, Kenneth W. Mahaffey
Summary: This study assessed the effects of canagliflozin on cardiovascular outcomes in patients with type 2 diabetes mellitus. The results showed that canagliflozin reduced the risk of cardiovascular death or hospitalization for heart failure, regardless of baseline renal function or level of albuminuria.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2022)
Article
Endocrinology & Metabolism
Katherine R. Tuttle, Adeera Levin, Masaomi Nangaku, Takashi Kadowaki, Rajiv Agarwal, Sibylle J. Hauske, Amelie Elsasser, Ivana Ritter, Dominik Steubl, Christoph Wanner, David C. Wheeler
Summary: This study assessed the safety of empagliflozin in patients with type 2 diabetes and moderate to severe chronic kidney disease. The findings showed that empagliflozin did not raise new safety concerns and may have beneficial effects on the development of hyperkalemia and edema.
Article
Endocrinology & Metabolism
Amy Kang, Brendan Smyth, Brendon L. L. Neuen, Hiddo J. L. Heerspink, Gian Luca Di Tanna, Hong Zhang, Clare Arnott, Carinna Hockham, Rajiv Agarwal, George Bakris, David M. M. Charytan, Dick de Zeeuw, Tom Greene, Adeera Levin, Carol Pollock, David C. C. Wheeler, Kenneth W. W. Mahaffey, Vlado Perkovic, Meg J. J. Jardine
Summary: The aim of this study was to assess the risk of non-genital skin and soft tissue infections (SSTIs) associated with the sodium-glucose cotransporter-2 (SGLT2) inhibitor canagliflozin. A post hoc analysis of two trials was conducted, and the results showed that canagliflozin did not significantly affect the risk of non-genital SSTIs or non-genital fungal SSTIs compared with placebo. This suggests that the changes in skin microenvironment mediated by SGLT2 inhibitors may not have meaningful clinical consequences.
DIABETES OBESITY & METABOLISM
(2023)
Article
Biochemistry & Molecular Biology
Raphaelle Corremans, Benjamin A. Vervaet, Geert Dams, Patrick C. D'Haese, Anja Verhulst
Summary: Diabetic Kidney Disease (DKD) is a common complication for diabetic patients and a leading cause of chronic kidney disease. The study compared the renoprotective effects of various antidiabetic drugs in a rat model of DKD and found that metformin and canagliflozin both showed protective effects against DKD progression.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Endocrinology & Metabolism
Kent Y. Feng, JingWei Li, Juliana Ianus, Dick de Zeeuw, Greg R. Fulcher, Michael Pfeifer, David R. Matthews, Meg J. Jardine, Vlado Perkovic, Bruce Neal, Kenneth W. Mahaffey
Summary: In the CANVAS program, the most common reasons for hospitalization were cardiac disorders, infections and infestations, and nervous system disorders. Canagliflozin, compared with placebo, reduced the rate of total ACH.
DIABETES OBESITY & METABOLISM
(2021)
Article
Cardiac & Cardiovascular Systems
Jie Yu, Jingwei Li, Phillip J. Leaver, Clare Arnott, Mark D. Huffman, Jacob A. Udell, Vlado Perkovic, Kenneth W. Mahaffey, Dick de Zeeuw, Greg Fulcher, David R. Matthews, Wayne Shaw, Norman Rosenthal, Bruce Neal, Gemma A. Figtree
Summary: Through a post hoc analysis of the CANVAS Programme and CREDENCE trial, it was found that canagliflozin did not show significant efficacy compared to placebo in patients with myocardial infarction. However, there may be a differential effect on STEMI and non-STEMI.
CARDIOVASCULAR RESEARCH
(2022)
Article
Cardiac & Cardiovascular Systems
Taha Sen, Jingwei Li, Brendon L. Neuen, Clare Arnott, Bruce Neal, Vlado Perkovic, Kenneth W. Mahaffey, Wayne Shaw, William Canovatchel, Michael K. Hansen, Hiddo J. L. Heerspink
Summary: In patients with type 2 diabetes at high cardiovascular risk, higher levels of GDF-15 were associated with increased risk of cardiovascular, HF, and kidney outcomes. Canagliflozin treatment modestly lowered GDF-15 levels, but the reduction in GDF-15 did not mediate the protective effect of canagliflozin on cardiovascular, HF, or kidney outcomes.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2021)
Article
Urology & Nephrology
Megumi Oshima, Meg J. Jardine, Rajiv Agarwal, George Bakris, Christopher P. Cannon, David M. Charytan, Dick de Zeeuw, Robert Edwards, Tom Greene, Adeera Levin, Soo Kun Lim, Kenneth W. Mahaffey, Bruce Neal, Carol Pollock, Norman Rosenthal, David C. Wheeler, Hong Zhang, Bernard Zinman, Vlado Perkovic, Hiddo J. L. Heerspink
Summary: The study found that in patients with type 2 diabetes and chronic kidney disease, the use of canagliflozin may lead to an acute drop in eGFR, but this did not affect long-term eGFR trajectories and safety outcomes.
KIDNEY INTERNATIONAL
(2021)
Article
Cardiac & Cardiovascular Systems
Brendon L. Neuen, Megumi Oshima, Vlado Perkovic, Rajiv Agarwal, Clare Arnott, George Bakris, Christopher P. Cannon, David M. Charytan, Robert Edwards, Jose L. Gorriz, Meg J. Jardine, Adeera Levin, Bruce Neal, Luca De Nicola, Carol Pollock, Norman Rosenthal, David C. Wheeler, Kenneth W. Mahaffey, Hiddo J. L. Heerspink
Summary: The study findings suggest that SGLT2 inhibition with canagliflozin may reduce the risk of hyperkalaemia in patients with type 2 diabetes mellitus and chronic kidney disease treated with renin-angiotensin-aldosterone system inhibitors without increasing the risk of hypokalaemia.
EUROPEAN HEART JOURNAL
(2021)
Article
Cardiac & Cardiovascular Systems
Yu Zhao, Li Li, Zongshi Lu, Yingru Hu, Hexuan Zhang, Fang Sun, Qiang Li, Chengkang He, Wentao Shu, Lijuan Wang, Tingbing Cao, Zhidan Luo, Zhencheng Yan, Daoyan Liu, Peng Gao, Zhiming Zhu
Summary: This study found a previously unrecognized role of TRPC3/NCX1 mediated vascular calcium dysfunction in the development of high-salt-induced hypertension, and Canagliflozin treatment can improve this dysfunction. These findings may provide a new therapeutic target for combating salt-sensitive hypertension.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2022)
Article
Endocrinology & Metabolism
Jie Yu, Arianne N. Sweeting, Chris Gianacas, Lauren Houston, Vivian Lee, Robert A. Fletcher, Vlado Perkovic, Qiang Li, Brendon L. Neuen, Otavio Berwanger, Hiddo J. L. Heerspink, Dick de Zeeuw, Clare Arnott
Summary: This study assessed the effects of canagliflozin on clinical outcomes and intermediate markers in patients with different BMI categories. The findings showed that canagliflozin reduced the risk of major adverse cardiovascular events and renal outcomes, with no differences in treatment effect across BMI subgroups. However, the effects of canagliflozin on body weight and blood pressure varied among different BMI subgroups.
DIABETES OBESITY & METABOLISM
(2023)
Article
Urology & Nephrology
Sjoukje van der Hoek, Niels Jongs, Megumi Oshima, Brendon L. L. Neuen, Jasper Stevens, Vlado Perkovic, Adeera Levin, Kenneth W. W. Mahaffey, Carol Pollock, Tom Greene, David C. C. Wheeler, Meg J. J. Jardine, Hiddo J. L. Heerspink
Summary: In the CREDENCE trial, canagliflozin was found to have a greater impact on eGFR slope in patients with higher baseline HbA1c levels, indicating that patients with poorer glycemic control may benefit more from the drug.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
(2023)
Article
Endocrinology & Metabolism
Taha Sen, Jingwei Li, Brendon L. Neuen, Bruce Neal, Clare Arnott, Chirag R. Parikh, Steven G. Coca, Vlado Perkovic, Kenneth W. Mahaffey, Yshai Yavin, Norman Rosenthal, Michael K. Hansen, Hiddo J. L. Heerspink
Summary: Higher plasma concentrations of TNFR-1, TNFR-2, and KIM-1 are associated with increased risk of kidney failure in individuals with type 2 diabetes. Canagliflozin can reduce these biomarkers, with early decreases in TNFR-1 and TNFR-2 independently associated with a lower risk of kidney disease progression.
Article
Transplantation
Marenao Tanaka, Kazuma Mori, Satoko Takahashi, Yukimura Higashiura, Hirofumi Ohnishi, Nagisa Hanawa, Masato Furuhashi
Summary: The study found a modest and independent association between MAFLD and new onset of CKD, and MAFLD was a better predictor for the development of CKD compared to FL or NAFLD.
NEPHROLOGY DIALYSIS TRANSPLANTATION
(2023)
Article
Urology & Nephrology
Norihito Moniwa, Ayumu Kimura, Ryo Nishikawa, Marenao Tanaka
Summary: This case study suggests that patients with very low ejection fraction are at high risk for contrast-induced nephropathy due to persistent retention of contrast medium in the kidney cortex.
Article
Cardiac & Cardiovascular Systems
Takuma Mikami, Masato Furuhashi, Ryosuke Numaguchi, Itaru Hosaka, Akiko Sakai, Marenao Tanaka, Toshiro Ito, Toshiyuki Maeda, Taku Sakurada, Satoshi Muraki, Yousuke Yanase, Hiroshi Sato, Joji Fukada, Yukihiko Tamiya, Yutaka Iba, Nobuyoshi Kawaharada
Summary: This study compared the characteristics of perivascular adipose tissue (PVAT) surrounding the saphenous vein (SV-PVAT) and subcutaneous adipose tissue (SCAT) in coronary artery bypass grafting. The results showed that SV-PVAT had larger adipocytes, less fibrosis, and different gene expression patterns compared to SCAT. This suggests that SV-PVAT is healthier and may play a role in the success of vascular grafting.
CIRCULATION JOURNAL
(2023)
Article
Peripheral Vascular Disease
Kazuma Mori, Marenao Tanaka, Itaru Hosaka, Takuma Mikami, Keisuke Endo, Nagisa Hanawa, Hirofumi Ohnishi, Masato Furuhashi
Summary: Metabolic dysfunction-associated fatty liver disease (MAFLD) is associated with an increase in systolic blood pressure (SBP) over time, and this association is stronger than that of fatty liver (FL) and nonalcoholic fatty liver disease (NAFLD). The rate of increase in SBP over time is higher in subjects with MAFLD compared to those without FL and those with FL but no MAFLD.
HYPERTENSION RESEARCH
(2023)
Article
Biochemistry & Molecular Biology
Megumi Watanabe, Tatsuya Sato, Yuri Tsugeno, Megumi Higashide, Masato Furuhashi, Hiroshi Ohguro
Summary: Comparison of the effects of three TGF-beta isoforms on HTM cells revealed that TGF-beta-3 had the most potent effect on TEER and FITC dextran permeability. However, TGF-beta-3 also induced different metabolic effects and had diverse effects on the physical properties and gene expression of ECM components in comparison to TGF-beta-1 and TGF-beta-2. These findings suggest that the unique action of TGF-beta-3 may play a role in the pathogenesis of glaucoma.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Cardiac & Cardiovascular Systems
Wataru Ohwada, Hidemichi Kouzu, Tatsuya Sato, Kahomi Sazawa, Azumi Matsui, Nobutaka Nagano, Masayuki Koyama, Noriko Ogasawara, Akifumi Takada, Toshiyuki Yano, Masato Furuhashi
Summary: Mitochondrial disease, caused by mtDNA mutation, can present with various phenotypes and affects glucose metabolism. The appropriate glycemic control strategy for patients with mitochondrial disease, especially those with muscle wasting, has not been established.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2023)
Article
Peripheral Vascular Disease
Marenao Tanaka, Tatsuya Sato, Keisuke Endo, Masafumi Inyaku, Kazuma Mori, Itaru Hosaka, Takuma Mikami, Yukinori Akiyama, Hirofumi Ohnishi, Nagisa Hanawa, Masato Furuhashi
Summary: A disorder of lipid metabolism is involved in cardiovascular diseases including hypertension. A high level of small dense low-density lipoprotein cholesterol (sdLDL-C) is a strong risk factor for atherosclerotic cardiovascular disease. However, the association between sdLDL-C and hypertension has not been fully investigated.
HYPERTENSION RESEARCH
(2023)
Article
Peripheral Vascular Disease
Keisuke Endo, Marenao Tanaka, Tatsuya Sato, Kazuma Mori, Itaru Hosaka, Takuma Mikami, Araya Umetsu, Yukinori Akiyama, Hirofumi Ohnishi, Nagisa Hanawa, Masato Furuhashi
Summary: Hypothyroidism has been found to be associated with chronic kidney disease (CKD). The study investigates the relationship between serum TSH levels and the development of CKD, finding that high TSH levels increase the risk of CKD in men but not in women.
HYPERTENSION RESEARCH
(2023)
Article
Biochemistry & Molecular Biology
Megumi Watanabe, Toshiyuki Yano, Tatsuya Sato, Araya Umetsu, Megumi Higashide, Masato Furuhashi, Hiroshi Ohguro
Summary: To establish an in vitro model for cardiomyocytes, 3D spheroids derived from H9c2 cardiomyoblasts were prepared and evaluated. The 3D H9c2 spheroids showed decreased size and increased stiffness, developing into a mature form without cell multiplication. The gene expressions and metabolic responses of the spheroids differed from 2D cultures, indicating their unique local environment.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Peripheral Vascular Disease
Masafumi Inyaku, Marenao Tanaka, Tatsuya Sato, Keisuke Endo, Kazuma Mori, Itaru Hosaka, Takuma Mikami, Araya Umetsu, Hirofumi Ohnishi, Yukinori Akiyama, Nagisa Hanawa, Masato Furuhashi
Summary: The calculated sdLDL-C level by Sampson's equation is a predominant predictor for the development of IHD in a general Japanese population.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS
(2023)
Meeting Abstract
Peripheral Vascular Disease
Marenao Tanaka, Kazuma Mori, Satoko Takahashi, Yukimura Higashiura, Hirofumi Ohnishi, Nagisa Hanawa, Masato Furuhashi
JOURNAL OF HYPERTENSION
(2023)
Article
Urology & Nephrology
Marenao Tanaka, Norihito Moniwa, Chieko Nogi, Toshiki Kano, Megumi Matsumoto, Akiko Sakai, Takuto Maeda, Hideki Takizawa, Yayoi Ogawa, Katsuhiko Asanuma, Yusuke Suzuki, Masato Furuhashi
Summary: The expression of fatty acid-binding protein 4 (FABP4) is increased in the glomerulus of patients with IgA nephropathy (IgAN), and urinary FABP4 level is associated with glomerular FABP4 expression. These findings suggest that glomerular FABP4 contributes to proteinuria in IgAN, and urinary FABP4 level can serve as a biomarker for evaluating glomerular damage.
JOURNAL OF NEPHROLOGY
(2023)
Article
Endocrinology & Metabolism
Maki Murakoshi, Nozomu Kamei, Yusuke Suzuki, Mitsunobu Kubota, Michiyoshi Sanuki, Hirotaka Tashiro, Takumi Iwasawa, Kazunori Kato, Marenao Tanaka, Masato Furuhashi, Tomohito Gohda
Summary: Elevated TNFR1, TNFR2, and EphA2 were associated with both kidney and composite outcomes in Japanese patients with diabetes.
DIABETES RESEARCH AND CLINICAL PRACTICE
(2023)